News

The current release is version 2.56.1 - Released April 28, 2026.  (Download the latest ICE release now)

Stay up-to-date! Please subscribe to the ICE Announcements E-mail List, or contact us at ice@hln.com and we can add your e-mail address for you. We send e-mail to this list only when there is important information to share about new (or upcoming) releases or information pertinent to the operation of ICE. It is a low-volume list direct from the ICE team and we do not share group members' e-mail addresses with anyone.

See also: ICE-related blogs on news and developments.

Prior News

• March 28, 2026 - New Release of ICE - Version 2.55.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.55.1 includes the following updates (please see the Release Notes for additional details): 

    • COVID-19 Pandemic: For shots prior to 9/12/2023 only, relaxed the evaluation logic for CVX 229 and CVX 230 vaccinations to potentially be marked Valid.

    • Hepatitis A: Added support for a 4-dose accelerated Twinrix series. Added alignment with Hepatitis B to coordinate Twinrix series recommendations if appropriate.

    • Hepatitis B: Added support for a 4-dose accelerated Twinrix series, added support for a Hep B 3-dose Twinrix Series. Added alignment with Hepatitis A to coordinate Twinrix series recommendations if appropriate.

    • Polio: Improved support for adult polio immunization; added supplemental text in the evaluation of unspecified polio to indicate that depending on what product was administered, additional protection may be needed; updated the implementation of the 4-dose series exception rules.

    • Core Service: Service start up time and response time of initial requests reduced. Supporting data has been converted from XML to YAML format, which enables runtime values to be changed via start up parameters.

  • The ICE Implementation Guide and ICE Implementation Guide Codes sheet have been updated to reflect a new evaluation reason code, new series, and new supplemental text.

  • The ICE wiki now includes additional information on rule alignment with clinical guidelines (e.g., ACIP/CDC, AAP, AAFP). Read more on the Clinical Guidelines page.

  • A new tool, CDS Insight, is now available to support demonstration and testing of the ICE service; check out this tool to see the latest ICE updates in action.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• March 2, 2026 - New Release of ICE - Version 2.53.2

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.53.2 includes the following updates: 

    • COVID-19 Seasonal: Addresses a logic gap in an evaluation special rule, addressed a series selection issue, and updated dose numbering in the <2 years series when doses span multiple seasons.

    • Dose Override feature: Corrects an issue that did not return an interpretation element when the requester indicates that a shot should be marked Invalid. (Only applicable if the enable-dose-override-feature is enabled.)

  • There are no changes to the ICE Implementation Guide or the ICE Implementation Guide Codes sheet. Please see the Release Notes for additional details.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• February 4, 2026 - New Release of ICE - Version 2.53.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.53.1 includes the following updates: 

    • COVID-19 Seasonal: Addressed an issue in limited circumstances where ICE was enforcing a 24-day absolute minimum interval from a prior season invalid Pfizer to a new season target dose rather than a 17-day interval.

    • Added support for four new vaccine groups:

      • Cholera

      • Japanese Encephalitis

      • Typhoid

      • Yellow Fever

    • Core service updates: 

      • Improved vaccine group inclusion/exclusion options in the application.yml file or via environment variable. Specifically:

        • An ICE instance can be configured with a full list of vaccine groups to support via the inclusion property, or via the exclusion property, all vaccine groups not to support. 

        • Out of the box, ICE supports the same set of vaccine groups as in the last release. That is, cholera, japanese encephalitis, typhoid and yellow fever vaccine groups must be individually enabled.

      • Ability to specify a boolean property in each vaccine group XML configuration if a vaccine group is "routine" or "non-routine".

  • The ICE Implementation Guide and ICE Implementation Guide Codes sheet has been updated to reflect updates related to the new vaccine groups, including vaccine, vaccine group, series, and supplemental text additions. A version of the Implementation Guide with changes highlighted since the last version is here.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• December 29, 2025 - New Release of ICE - Version 2.52.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.52.1 includes the following updates: 

    • COVID-19 Seasonal: Updated intervals from a prior season Pfizer to a 2025-2026 season target dose Moderna for patients under 2 years, in line with a November American Academy of Pediatrics update.

    • Core service updates: Implemented several "under the hood" technical improvements, including upgrades to Java 25, Drools 10, and OpenCDS 7.0.1. Additionally, the service can now run on Spring Boot as well as Tomcat.

  • See the revised installation instructions given the core service updates. There are no updates to the ICE Implementation Guide Codes sheet. Please see the Release Notes for additional details.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• November 18, 2025 - New Release of ICE - Version 2.51.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.51.1 includes the following updates: 

    • COVID-19 Seasonal: Added support for the 2025-2026 season, with a season start date of 8/27/2025. The 2025-2026 season rules are aligned with American Academy of Pediatrics recommendations for patients through age 18 years and American Academy of Family Physicians recommendations for children/adolescents and adults. Added support for CVX 334, COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL, Moderna (mNEXSPIKE, 12+ yrs).

    • COVID-19 Pandemic: Added a vaccine start date of 12/11/2020 for CVX 211 and CVX 213.

    • Mpox: Updated references from “orthopoxvirus” to “mpox”. Added support for CVX 325, vaccinia (smallpox, mpox), unspecified (NOS). Updated live vaccine interval handling for mpox vaccines.

    • General Rules: Added two new general rules: Evaluation of Shots Prior to the CVX Start Date and Evaluation of Shots After the CVX End Date. 

    • Core Service: Updated the ICE service from Java 17 to Java 21.  The Java update requires users who download the zipfile distribution to upgrade to Java 21. Also, the service can now be used with either Tomcat 10 or Tomcat 11; previously, Tomcat 11 was not supported.

    • The ICE Implementation Guide Codes sheet has been updated to reflect the following: 

      • The addition of CVX 334 and CVX 325, as well as COVID-19 and mpox vaccine name updates. 

      • The three new series for the COVID-19 2025-2026 season.

      • New Supplemental Text for the 2025-2026 COVID-19 season.

    • Please see the Release Notes for additional details.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• September 2nd, 2025 - New Release of ICE - Version 2.48.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.48.1 includes the following updates: 

    • Influenza: Added support for CVX 333 (Influenza, live, intranasal, self/caregiver admin) and CVX 331 (Influenza Southern Hemisphere trivalent vaccine). Updated the CVX 201 vaccine name to reflect 'quadrivalent' (Influenza, Southern Hemisphere, quadrivalent).  

    • RSV: Added support for CVX 332 (RSV, mAb, 0.7 mL, age 0 - < 8 mos. (clesrovimab)). Updated the CVX 306 and CVX 307 vaccine names to reflect 'nirsevimab.' Lowered the age for the Conditional risk-based recommendation for adult RSV from 60 years to 50 years. 

    • The ICE Implementation Guide Codes sheet has been updated to reflect the following: 

      • The addition of CVX 333, CVX 331, and CVX 332.

      • The CVX 201, CVX 306, and CVX 307 vaccine name updates.

      • Modified SUPPLEMENTAL_TEXT, descriptive text used in RSV.

    • Please see the Release Notes for additional details.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • The ICE team continues to monitor and review updates related to COVID-19 recommendations for the 2025-2026 season, including recommendations recently published by the American Academy of Pediatrics. A forthcoming ICE release will address updated COVID-19 recommendations.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• June 27, 2025 - New Release of ICE - Version 2.47.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.47.1 includes the following updates: 

    • Hepatitis A: Modified the series selection rules to limit selection of the 3-dose series to when CVX 104 (Twinrix) is administered to an adult patient as dose 1 and/or dose 2; when Twinrix is not used, ICE will evaluate and forecast in the 2-dose series, where a 6-month interval is required between doses. Added absolute minimum ages and absolute maximum ages to Hepatitis A vaccines; the addition of the absolute maximum age will invalidate pediatric formulations of the vaccines when given to patients 19 years and older, in line with recommendations to repeat the dose. Modified the 2-dose series and the 3-dose series.

    • Hib: Updated the booster dose handling of CVX 50 in the Hib OMP series.

    • MMR: Updated the evaluation of MMR at 6 - 11 months from Invalid to Accepted, given MMR may be given at this age for high-risk patients. Updated the dose 1 and dose 2 absolute minimum age to months/years instead of days.

    • Orthopoxvirus: Updated the CVX 75 name to “Vaccinia (smallpox, mpox), live”.

    • Pneumococcal:

      • Updated adult logic to align with the latest guidelines, including lowering the recommended age for the first adult vaccination from 65 years to 50 years. 

      • Added support for CVX 327 (PCV21) and CVX 177 (PCV10). 

      • Lowered PCV20 allowable age for the childhood series.

      • Improved handling of duplicate pneumococcal shots recorded on the same day.

      • For the zip file distribution only: added property setting in ice.properties, disable_output_earliest_and_overdue_dates_for_pneumococcal_adult_series. If set to "Y", ICE will not output the earliest and overdue dates for the Adult Pneumococcal Series. By default, this setting is disabled.

    • Polio: Updated the CVX 02 name to “OPV, trivalent” and updated the CVX 89 name to Polio, unspecified formulation (NOS) (no logic changes).

    • RSV: Updated recommendation for patients age 8 - < 20 months old who completed their infant series from Conditional / HIGH_RISK to Conditional / COMPLETE_HIGH_RISK; this supports identification of children in this age range who completed the RSV infant series as compared to those who did not.

    • General Rule: Live Vaccine Interval: Update to ensure enforcement of a 28-day absolute minimum interval between MMRV and another live vaccine.

    • The ICE Implementation Guide Codes sheet has been updated to reflect the following: 

      • The polio and orthopoxvirus vaccine name updates

      • The addition of CVX 327, and CVX 177

      • The addition of new recommendation reason codes: ADMINISTER_PCV15_PCV20_OR_PCV21, ADMINISTER_PCV20_OR_PCV21

      • Modified and new SUPPLEMENTAL_TEXT, descriptive text used in pneumococcal.

    • Please see the Release Notes for additional details.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• April 26, 2025 - New Release of ICE - Version 2.46.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.46.1 includes the following updates: 

    • Meningococcal B: Added support for the updated dosing intervals and schedule for the Bexsero MenB-4C vaccine (ICE now supports the previous MenB-4C schedule and the updated MenB-4C schedule as of October 25, 2024). Added support for CVX 328, Meningococcal MenABCWY (Penmenvy).

    • Meningococcal: Added support for CVX 328, Meningococcal MenABCWY (Penmenvy). Updated the CVX 108 vaccine name from "Meningococcal, unspecified formulation" to "Meningococcal ACWY, unspecified formulation" for additional clarity and alignment with the CDC CVX name (wiki update only; no logic changes for CVX 108). 

    • COVID-19 - Seasonal: Addressed an issue to ensure a vaccine group-level recommendation (rather than CVX-level recommendation) when indicated in the rules. Additionally, addressed a rare processing error.

    • The ICE Implementation Guide Codes sheet has been updated to reflect the addition of a Meningococcal B series, the vaccine name change for CVX 108, the new CVX 328, and the addition of supplemental text descriptive text used in Meningococcal B.

    • Please see the Release Notes for additional details. 

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • Forthcoming ICE releases: Upcoming ICE releases will address changes in the Pneumococcal vaccine group and adult RSV updates from the April 15-16, 2025 ACIP meeting.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• February 18, 2025 - New Release of ICE - Version 2.45.2

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.45.2 fixes an issue discovered in v2.45.1 where the HPV minimum age was changed from 9 years to 11 years. This was an inadvertent change in the files included in the final v2.45.1 release. Version 2.45.2 resets the HPV minimum age to 9 years.

  • For information about what is included in version 2.45, please see the News entry below and the Release Notes.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • Our sincere apologies for this error. If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• February 17, 2025 - New Release of ICE - Version 2.45.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.45.1 includes the following updates: 

    • COVID-19: Added support for the 23-24 season additional dose for patients 65 years and older; added support for the 24-25 season recommendations, including the additional dose for patients 65 years and older. Several updates to ensure alignment with the latest recommendations. 

    • Hepatitis B: Series selection implementation updates to ensure the appropriate series is selected in certain circumstances.

    • Hib: Added CVX 132 to the implementation files for the Hib 4-dose Series (no wiki rule change). 

    • RSV: Updated the display name for CVX 307 in the configuration files (no wiki rule changes). Updated the rules to support validation of infant RSV CVX codes starting on 8/3/2023 and to support validation of adult and otherwise unspecified RSV CVX codes starting on 6/21/2023. Updated the supplemental text to remove special characters (apostrophe and en dash). 

    • Zoster: Updated the implementation of the minimum interval between a CVX 121 or CVX 188 to a CVX 187 to 56 days rather than 28 days, to align with the wiki rules.

    • Additional Updates: Addressed an issue with supplemental text, where, in some circumstances, supplemental text associated with one vaccine group appeared in the forecast output for a different vaccine group. 

    • The ICE Implementation Guide Codes sheet has been updated to reflect the changes in the RSV supplemental text. 

    • Please see the Release Notes for additional details. 

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • Forthcoming ICE releases: Upcoming ICE release will address changes in the Pneumococcal and Meningococcal B vaccine groups.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• November 1, 2024 - New Release of ICE - Version 2.44.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.44.1 includes the following updates: 

    • DTP: Added a minimum recommended age of 7 years in the DTP 5-dose series when the Six by Seven rule applies.

    • Influenza: Updated wiki to reflect the 2024-2025 season. Influenza 2024-2025 Season rules remain unchanged from last season. Note: There are no evaluation and forecasting changes for the 2024-2025 season.

    • RSV: Added support for a new RSV Vaccine Group and two RSV series: RSV Infant Series (seasonal series for infants younger than 8 months of age) and RSV Adult Series (for adults age 75 years and older). Added support for RSV vaccines: CVX 303, CVX 304, CVX 305, CVX 306, CVX 307, CVX 314, CVX 315, CVX 326.

    • The ICE Implementation Guide and the ICE Implementation Guide Codes sheet have been updated to include the new RSV vaccine group, RSV series, and the RSV CVX codes. Please see the Release Notes for details. 

  • A functionally equivalent v1.44.1 is also available; however, users are encouraged to transition to version 2. This will be the last version 1 release. Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • Forthcoming ICE releases: The next ICE release will address COVID-19 updates.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

  • Note: The ICE Announcement email about this new release also referenced an implementation change to the Zoster vaccine group. That change will be included in a future ICE release; the Zoster vaccine group remains unchanged with version 2.44.1.

• August 19, 2024 - New Release of ICE - Version 2.43.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 2.43.1 provides core service updates to transition the ICE service to Java 17, Tomcat 10, OpenCDS v6, and Spring v6.

    • This release is functionally equivalent to v1.43.1. There are no changes to the ICE Implementation Guide or the ICE Implementation Guide Codes sheet. Please see the Release Notes for details. 

    • Users are encouraged to transition to v2 (Java 17/Tomcat 10). Release v1.43.1 continues to be available, and one subsequent v1 (Java 8/Tomcat 9) release will be made available to ensure users can successfully transition.

    • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • Forthcoming ICE releases:

    • The next ICE release (v2.44.1/v1.44.1) is anticipated by early September. This release will address COVID-19 updates to support the additional dose recommendation for adults ages 65 years and older. This is expected to be the last v1 release.

    • A subsequent ICE release (v2.45.1), will provide support for infant and adult RSV recommendations, including the updated adult RSV recommendations adopted by ACIP in June 2024. With this release, ICE will be fully transitioned to v2.

  • As always, we continue to monitor updates to immunization recommendations. We will work to incorporate anticipated updated COVID-19 recommendations for the 2024-2025 season into ICE in a timely manner.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• July 17, 2024 - Upcoming Transition to ICE v2

  • In addition to ongoing work to ensure ICE alignment with ACIP recommendations, we've also been working on core updates to the ICE service. We will soon release ICE v2.43.1, a production-ready transition release that updates the ICE service to Java 17, Spring v6, OpenCDS v6, and Tomcat 10. This release will be functionally equivalent to release v1.43.1.

  • Since ICE runs in a variety of environments, we suggest you plan to complete additional testing to ensure there are no issues with your installation/with running v2.43.1 in your environment. Release v1.43.1 will continue to be available in case you encounter challenges.

  • For subsequent releases over the short term, we will continue to have two versions of ICE available: v1, which runs on Java 8, and a functionally equivalent v2 with the core updates. We welcome your testing feedback to ensure ICE users can successfully transition to v2.

  • If you have any questions, comments, or suggestions, please reach out to us at ice@hln.com.

• June 21, 2024 - New Release of ICE - Version 1.43.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 1.43.1 includes the following additions and changes. Please see the Release Notes for details.

    • Meningococcal B: Added support for CVX 316, Meningococcal MenABCWY (Penbraya). Addressed an issue in the series selection rules that resulted in (under certain circumstances) the incorrect series being selected.

    • Meningococcal ACWY: Added support for CVX 316, Meningococcal MenABCWY (Penbraya).

    • Influenza: Added support for CVX 320, Influenza, MDCK, trivalent, preservative.

    • DTP: Added recommendation reason codes ADMINISTER_TDAP_OR_TD and SUPPLEMENTAL_TEXT, with descriptive text, "Administer either Tdap or Td" to the recurring booster dose recommendation. 

    • MMR: Addressed an issue in the proof of immunity logic. 

    • Varicella: Addressed an issue in the proof of immunity and disease documented logic.

    • Hep A / Hep B: Addressed an issue in the proof of immunity logic. 

    • A new property, disable_covid19_sep2023_dose_number_reset, was added to the ice.properties file. If enabled, ICE will not reset the dose number to 1 when recommending the Sept 2023 COVID-19 >= 5y series.  This option is disabled by default, aligning with the behavior in the last version.

  • The ICE Implementation Guide has been updated to include CVX 316 and CVX 320.

  • A Google Sheet that lists all the coded values in the Implementation Guide is also available. 

  • Upcoming Releases:

    • Forthcoming ICE updates will include the introduction of a new RSV vaccine group to support RSV evaluation and recommendations for infants and older adults, and support for an additional dose recommendation of COVID-19 for adults ages 65 years and older.

    • An ICE software upgrade to Java 17, OpenCDS v6, and Tomcat 10. The Java 17/Tomcat10 will ultimately replace the current Java 8/Tomcat 9 version and a test version will be available in July. So that users have time to test the new Java 17/Tomcat 10 version in their environments, the ICE team will provide both Java 17/Tomcat 10 and Java 8/Tomcat 9 versions for a couple of releases before fully deprecating the Java 8/Tomcat 9 version entirely.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • If you have any questions, comments, or suggestions, please e-mail us at ice@hln.com.

• March 18, 2024 - New Release of ICE - Version 1.42.1.4

  • A new release of ICE is available - Download the latest ICE release now.

  • 1.42.1.4 fixes a dose numbering issue for young patients who are continuing in an < 5 years series after 9/12/2023, clarifies a special rule in the >= 5 year series and corresponding logic to address an exception related to the handling of CVX 313, and extends the "start" date for COVID-19 vaccines in the prior season. 

  • For information about what is included in version 1.42.1, please see the News entry below and the Release Notes.

  • If you have any questions, comments, or suggestions, please do not hesitate to e-mail us at ice@hln.com.

• March 7th, 2024 - New Release of ICE - Version 1.42.1.3

  • A new release of ICE is available - Download the latest ICE release now.

  • 1.42.1.3 fixes an issue discovered in v1.42.1.2. In certain situations, some historical COVID doses prior to September 12, 2023 were being evaluated as Accepted rather than Valid. This release fixes this issue.

  • For information about what is included in version 1.42.1, please see the News entry below and the Release Notes.

  • If you have any questions, comments, or suggestions, please do not hesitate to e-mail us at ice@hln.com.

• March 5th, 2024 - New Release of ICE - Version 1.42.1.2

  • Version 1.42.1.2 fixes an issue that was discovered in version 1.42.1. Some shots in the >= 5 year COVID-19 series were incorrectly being evaluated as Invalid. Those who download version 1.42.1 will need to upgrade to this release which addresses this issue.

  • For information about what is included in version 1.42, please see the News entry below and the Release Notes.

  • If you have any questions, comments, or suggestions, please do not hesitate to e-mail us at ice@hln.com.

• March 1st, 2024 - New Release of ICE - Version 1.42.1

  • Version 1.42.1 includes updates to support the COVID-19 recommendations introduced on September 12, 2023. These recommendations are supported by an additional set of logic for the COVID-19 Vaccine Group. The new COVID-19 - September 2023 Onwards logic includes five series and adds support for the updated (2023–2024 formula) COVID-19 vaccines: CVX 309, CVX 310, CVX 311, CVX 312, and CVX 313. See the Release Notes for additional details.

  • The ICE Implementation Guide has been updated with the new COVID-19 codes: CVX 309, CVX 310, CVX 311, CVX 312, and CVX 313, and the new Sept 2023 COVID-19 series names. 

  • A Google Sheet that lists all the coded values in the Implementation Guide is also available. 

  • Forthcoming ICE updates will include the introduction of a new RSV Vaccine Group, to support RSV recommendations for infants and older adults, as well as updates to the COVID-19 – September 2023 Onwards logic. The COVID-19 – September 2023 Onward logic update will address the February 28, 2024, ACIP vote and subsequent CDC endorsement of the recommendation for adults ages 65 years and older to receive an additional dose of the updated 2023-2024 COVID-19 vaccine.

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • If you have any questions, comments, or suggestions, please e-mail us at ice@hln.com.

• November 3, 2023 - New Release of ICE - Version 1.41.1

  • A new release of ICE is available - Download the latest ICE release now.

  •  See the Release Notes for additional details.Version 1.41.1 includes updates to the Pneumococcal vaccine group to support 20-valent pneumococcal conjugate vaccine (PCV20) use in children.

  • There are no changes to the ICE Implementation Guide with this release. A Google Sheet that lists all of the coded values in the Implementation Guide is also available. 

  • The ICE team is continuing work on enhancements to address new recommendations for COVID-19 and RSV. Releases with support for these changes are forthcoming. 

  • Not sure which version of ICE you're currently using? View the README.HISTORY file included with each zipfile distribution or pull the version dynamically at the following endpoint: http(s)://<host>:<port>/path/to/opencds-decision-support-service/version.

  • If you have any questions, comments, or suggestions, please e-mail us at ice@hln.com.

• October 24, 2023 - ICE updates for pneumococcal, COVID-19, and RSV expected

  • The HLN ICE team continues to work on updates to ICE to address the latest recommendations for pneumococcal, COVID-19, and RSV. There will be multiple releases to address these changes, with release 1.41.1 expected next week.

  • Release 1.41.1 will include updates to the pneumococcal vaccine group to support the use of 20-valent pneumococcal conjugate vaccine in children. Look for an ICE Announcement indicating the availability of this release.

  • Future ICE releases will address the latest recommendations for COVID-19 and RSV. ICE support for RSV will include the seasonal recommendation for infant monoclonal antibody administration and the shared clinical decision-making recommendation for adults aged 60 years and older.

  • Please don't hesitate to reach out to us at ice@hln.com if you have any questions.

• October 6, 2023 - New Release of ICE - Version 1.40.1

  • A new release of ICE is available - Download the latest ICE release now.

  • Version 1.40.1 includes updates to an ICE General Rule and updates to the following vaccine groups: DTP, Influenza, MMR, and Varicella. A summary follows. See the Release Notes for additional details.